FLEX proves that cetuximab combo can extend survival in all metastatic NSCLC

    loading  Checking for direct PDF access through Ovid

Abstract

▪ In a plenary session at the conference, researchers reported that cetuximab, when combined with chemotherapy, can prolong survival in patients with metastatic NSCLC, irrespective of whether they have squamous or non-squamous histologies.

Related Topics

    loading  Loading Related Articles